Elizabeth M Everson1, Jonah D Hocum1, Grant D Trobridge1,2. 1. Department of Pharmaceutical Sciences, Washington State University College of Pharmacy, WSU Spokane, Spokane, WA, USA. 2. School of Molecular Biosciences, Washington State University, Pullman, WA, USA.
Abstract
BACKGROUND: Previous studies have shown that foamy viral (FV) vectors are a promising alternative to gammaretroviral and lentiviral vectors and also that insulators can improve FV vector safety. However, in a previous analysis of insulator effects on FV vector safety, strong viral promoters were used to elicit genotoxic events. In the present study, we developed and analyzed the efficacy and safety of a high-titer, clinically relevant FV vector driven by the housekeeping promoter elongation factor-1α and insulated with an enhancer blocking A1 insulator (FV-EGW-A1). METHODS: Human CD34+ cord blood cells were exposed to an enhanced green fluorescent protein expressing vector, FV-EGW-A1, at a multiplicity of infection of 10 and then maintained in vitro or transplanted into immunodeficient mice. Flow cytometry was used to measure engraftment and marking in vivo. FV vector integration sites were analyzed to assess safety. RESULTS: FV-EGW-A1 resulted in high-marking, multilineage engraftment of human repopulating cells with no evidence of silencing. Engraftment was highly polyclonal with no clonal dominance and a promising safety profile based on integration site analysis. CONCLUSIONS: An FV vector with an elongation factor-1α promoter and an A1 insulator is a promising vector design for use in the clinic.
BACKGROUND: Previous studies have shown that foamy viral (FV) vectors are a promising alternative to gammaretroviral and lentiviral vectors and also that insulators can improve FV vector safety. However, in a previous analysis of insulator effects on FV vector safety, strong viral promoters were used to elicit genotoxic events. In the present study, we developed and analyzed the efficacy and safety of a high-titer, clinically relevant FV vector driven by the housekeeping promoter elongation factor-1α and insulated with an enhancer blocking A1 insulator (FV-EGW-A1). METHODS:HumanCD34+ cord blood cells were exposed to an enhanced green fluorescent protein expressing vector, FV-EGW-A1, at a multiplicity of infection of 10 and then maintained in vitro or transplanted into immunodeficientmice. Flow cytometry was used to measure engraftment and marking in vivo. FV vector integration sites were analyzed to assess safety. RESULTS:FV-EGW-A1 resulted in high-marking, multilineage engraftment of human repopulating cells with no evidence of silencing. Engraftment was highly polyclonal with no clonal dominance and a promising safety profile based on integration site analysis. CONCLUSIONS: An FV vector with an elongation factor-1α promoter and an A1 insulator is a promising vector design for use in the clinic.
Authors: M E Olszko; J E Adair; I Linde; D T Rae; P Trobridge; J D Hocum; D J Rawlings; H-P Kiem; G D Trobridge Journal: Gene Ther Date: 2015-03-19 Impact factor: 5.250
Authors: Michael Aaron Goodman; Paritha Arumugam; Devin Marie Pillis; Anastacia Loberg; Mohammed Nasimuzzaman; Danielle Lynn; Johannes Christiaan Maria van der Loo; Phillip Joseph Dexheimer; Mehdi Keddache; Thomas Roy Bauer; Dennis Durand Hickstein; David William Russell; Punam Malik Journal: J Virol Date: 2017-12-14 Impact factor: 5.103
Authors: Marion G Ott; Manfred Schmidt; Kerstin Schwarzwaelder; Stefan Stein; Ulrich Siler; Ulrike Koehl; Hanno Glimm; Klaus Kühlcke; Andrea Schilz; Hana Kunkel; Sonja Naundorf; Andrea Brinkmann; Annette Deichmann; Marlene Fischer; Claudia Ball; Ingo Pilz; Cynthia Dunbar; Yang Du; Nancy A Jenkins; Neal G Copeland; Ursula Lüthi; Moustapha Hassan; Adrian J Thrasher; Dieter Hoelzer; Christof von Kalle; Reinhard Seger; Manuel Grez Journal: Nat Med Date: 2006-04-02 Impact factor: 53.440
Authors: Brian C Beard; Kirsten A Keyser; Grant D Trobridge; Laura J Peterson; Daniel G Miller; Michael Jacobs; Rajinder Kaul; Hans-Peter Kiem Journal: Hum Gene Ther Date: 2007-05 Impact factor: 5.695
Authors: Christian Jörg Braun; Kaan Boztug; Anna Paruzynski; Maximilian Witzel; Adrian Schwarzer; Michael Rothe; Ute Modlich; Rita Beier; Gudrun Göhring; Doris Steinemann; Raffaele Fronza; Claudia Regina Ball; Reinhard Haemmerle; Sonja Naundorf; Klaus Kühlcke; Martina Rose; Chris Fraser; Liesl Mathias; Rudolf Ferrari; Miguel R Abboud; Waleed Al-Herz; Irina Kondratenko; László Maródi; Hanno Glimm; Brigitte Schlegelberger; Axel Schambach; Michael Heinrich Albert; Manfred Schmidt; Christof von Kalle; Christoph Klein Journal: Sci Transl Med Date: 2014-03-12 Impact factor: 17.956
Authors: Elizabeth M Everson; Miles E Olzsko; David J Leap; Jonah D Hocum; Grant D Trobridge Journal: Mol Ther Methods Clin Dev Date: 2016-08-17 Impact factor: 6.698